Silymarin for treatment of adults with nonalcoholic fatty liver disease

This is a protocol for a Cochrane Review (intervention). The objectives are as follows:

To evaluate the benefits and harms of silymarin in adults with nonalcoholic fatty liver disease (NAFLD).

This is a protocol.

Published:

5 April 2023

Authors:

Wang C, Kanaan G, Shang Y, Chai L, Li H, Qi X

Was this helpful? Donate.

If you found this evidence helpful, please consider donating to Cochrane. We are a charity that produces accessible evidence to help people make health and care decisions.
Donate
Print
PDF
Citation
Wang C, Kanaan G, Shang Y, Chai L, Li H, Qi X. Silymarin for treatment of adults with nonalcoholic fatty liver disease (Protocol). Cochrane Database of Systematic Reviews 2023, Issue 4. Art. No.: CD015524. DOI: 10.1002/14651858.CD015524.